Viking Therapeutics (VKTX) Misses Q2 EPS by 2c

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11).

"Viking continued to make excellent progress with multiple programs in the second quarter," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "With respect to VK5211, our novel selective androgen receptor modulator (SARM), we are honored to have an opportunity to present the results of our Phase 2 study in hip fracture patients at the plenary session of the upcoming conference of the American Society for Bone and Mineral Research. We are also very pleased to have completed enrollment in the Phase 2 trial of our novel thyroid receptor beta agonist VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL cholesterol. We look forward to reporting the results from this study in the fall. Finally, both of our rare disease programs continued to advance toward clinical development. With respect to our glycogen storage disease (GSD) Ia program, we expect to initiate dosing with VK2809 in a proof-of-concept study later this quarter. And, with respect to our VK0214 program in X-linked adrenoleukodystrophy (X-ALD), we are conducting the pre-IND work that should allow us to initiate a proof-of-concept trial in 2019."

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Altria (MO) delivers in-line earnings, revenue in Q1; shares slightly up
• Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c